ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,275.38
0.54%
Dow Jones
38,686.32
1.51%
Gold vs US Dollar
2,327.355
0.00%
Brent Oil
81.295
0.00%
Bitcoin
67,584.09
0.15%
Pepperstone
Advertisement
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Europe
  5. EU
  6. Ab Science (AB)

  7. Ab Science (AB) News

Ab Science (AB)

Ab Science
Date:
Sort by:
 Showing the most relevant articles for your search:EU:AB
DateTimeSourceHeadlineSymbolCompany
31/05/202415:30GlobeNewswire Inc.AB Science is providing a summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALSEU:ABAb Science
31/05/202415:30GlobeNewswire Inc.AB Science is providing a summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALSEU:ABAb Science
31/05/202415:30GlobeNewswire Inc.AB Science fournit un résumé de la conférence virtuelle qui s'est tenue le 30 mai 2024, faisant le point sur la demande d'autorisation de mise sur le marché conditionnelle du masitinib dans la SLAEU:ABAb Science
29/05/202417:02GlobeNewswire Inc.AB Science fait le point sur la demande d'autorisation de mise sur le marché conditionnelle du masitinib dans la SLAEU:ABAb Science
29/05/202417:02GlobeNewswire Inc.AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALSEU:ABAb Science
29/05/202417:02GlobeNewswire Inc.AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALSEU:ABAb Science
17/05/202416:58GlobeNewswire Inc.AB Science communique un rectificatif sur les comptes consolidés au 31 décembre 2023EU:ABAb Science
15/05/202419:16GlobeNewswire Inc.AB Science reports its revenues for the year 2023 and provides an update on its activitiesEU:ABAb Science
15/05/202419:16GlobeNewswire Inc.AB Science annonce ses résultats financiers annuels arrêtés au 31 décembre 2023 et présente un point sur ses activitésEU:ABAb Science
15/05/202419:16GlobeNewswire Inc.AB Science reports its revenues for the year 2023 and provides an update on its activitiesEU:ABAb Science
13/05/202417:08GlobeNewswire Inc.AB Science announces issuance of a European patent for masitinib in the treatment of severe mastocytosis with protection until 2036EU:ABAb Science
13/05/202417:08GlobeNewswire Inc.AB Science annonce la délivrance d’un brevet européen pour le masitinib dans le traitement de la mastocytose sévère avec une protection jusqu’en 2036EU:ABAb Science
13/05/202417:08GlobeNewswire Inc.AB Science announces issuance of a European patent for masitinib in the treatment of severe mastocytosis with protection until 2036EU:ABAb Science
07/05/202417:05GlobeNewswire Inc.AB Science : A new publication in the medical journal Muscle & Nerve validates the use of the rate of decline of ALSFR-S score (ΔFS) for the design of clinical studies and the treatment choice for amyotrophic lateral sclerosis (ALS) patientEU:ABAb Science
07/05/202417:05GlobeNewswire Inc.AB Science : A new publication in the medical journal Muscle & Nerve validates the use of the rate of decline of ALSFR-S score (ΔFS) for the design of clinical studies and the treatment choice for amyotrophic lateral sclerosis (ALS) patientEU:ABAb Science
07/05/202417:05GlobeNewswire Inc.AB Science:EU:ABAb Science
02/05/202418:14GlobeNewswire Inc.AB Science : The Paris Court of Appeal confirms the acquittal of the CEO of AB Science, Alain Moussy, and reduces the amount of the financial penalty imposed on AB ScienceEU:ABAb Science
02/05/202418:14GlobeNewswire Inc.AB Science : The Paris Court of Appeal confirms the acquittal of the CEO of AB Science, Alain Moussy, and reduces the amount of the financial penalty imposed on AB ScienceEU:ABAb Science
02/05/202418:14GlobeNewswire Inc.AB Science : La Cour d’Appel de Paris confirme la mise hors de cause du Président Directeur Général d’AB Science, Alain Moussy, et diminue le montant de la sanction imposée à AB ScienceEU:ABAb Science
30/04/202417:56GlobeNewswire Inc.AB Science announces a slight delay in the publication of its 2023 annual financial reportEU:ABAb Science
30/04/202417:56GlobeNewswire Inc.AB Science announces a slight delay in the publication of its 2023 annual financial reportEU:ABAb Science
30/04/202417:56GlobeNewswire Inc.AB Science annonce un léger décalage de la publication de son rapport financier annuel 2023EU:ABAb Science
03/04/202417:08GlobeNewswire Inc.AB Science annonce que Santé Canada a jugé admissible la demande de réexamen du masitinib dans SLAEU:ABAb Science
03/04/202417:08GlobeNewswire Inc.AB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALSEU:ABAb Science
13/03/202411:58GlobeNewswire Inc.AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative diseaseEU:ABAb Science
13/03/202411:58GlobeNewswire Inc.AB Science : De nouvelles recherches montrent que le masitinib limite les dommages neuronaux dans un modèle de maladie neurodégénérative d’origine neuroimmuneEU:ABAb Science
13/03/202411:58GlobeNewswire Inc.AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative diseaseEU:ABAb Science
07/03/202414:20GlobeNewswire Inc.AB Science provides a summary of the live webcast held on March 4, 2024 giving an update on AB Science developmentEU:ABAb Science
07/03/202414:20GlobeNewswire Inc.AB Science propose un résumé de la conférence virtuelle qui s’est tenue le 4 mars 2024, avec pour objectif de faire le point sur le développement d'AB ScienceEU:ABAb Science
07/03/202414:20GlobeNewswire Inc.AB Science provides a summary of the live webcast held on March 4, 2024 giving an update on AB Science developmentEU:ABAb Science
 Showing the most relevant articles for your search:EU:AB

Your Recent History

LSE
BIRD
Blackbird
LSE
POS
Plexus
LSE
ITV
Itv
LSE
VAST
Vast Resources
LSE
GOLD
LSE
GKP
Gulf Keystone Petroleum
LSE
NG.
National Grid
LSE
LLOY
Lloyds Banking
LSE
SCLP
Scancell
LSE
TERN
Tern
LSE
SAR
Sareum
LSE
AAZ
Anglo Asian Mining
LSE
KRS
Keras Resources
LSE
CNR
Condor Gold
LSE
SYME
Supply@me Capital
LSE
BLOE
Block Energy
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved